In addition to IL-24 and IL-12, Sun et al. investigated whether recombinant adenoviruses expressing IL-2 (rAd-IL-2) as a gene immunotherapy agent could optimize the prognosis of HCC patients (53). Here, IL2 is linked to hepatocellular carcinoma.